Adularia

Adularia AG is a Swiss biotechnology company specializing in the development of precision cancer immunotherapies. Originally founded as Recolony, the company pivoted its strategic focus from microbiome-based live biotherapeutic products to the development of synthetic small molecule therapies. Their approach is based on the discovery of a molecular mechanism where bacterial metabolites activate tumor-residing macrophages, which in turn trigger a potent anti-tumor immune reaction via cytotoxic T-cells. By engineering small molecules that replicate this natural process, the company aims to enhance the body's native immune response while limiting off-target effects and maximizing therapeutic efficacy.

The company utilizes AI-powered drug discovery, combining physics-informed machine learning with generative models to accelerate the identification and optimization of drug candidates. This technology enables the design of molecules with improved affinity, selectivity, and stability. Based in Zurich and affiliated with the Wyss Zurich Translational Center, Adularia focuses on creating next-generation oncology treatments that offer more effective, targeted options for patients. Their work is supported by various research foundations and academic partnerships, aiming to redefine immunotherapy through a deep understanding of the interplay between the human microbiome, the immune system, and cancer progression.